Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05840159 · ClinicalTrials.gov registry record · Phase 4
A Study of Doxycycline to Treat Chlamydial Infection
A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 526
- Enrollment target
NCT05840159 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 526 participants.
The verdict
NCT05840159, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 526 participants
- Enrollment target
Study Summary
This is a Phase 4 blinded, randomized, active-controlled, non-inferiority trial. Final evaluable population will include a minimum 596 individuals: 298 women with confirmed urogenital chlamydia (CT) and 298 men with confirmed rectal chlamydia (CT). Approximately 664 participants will be enrolled to achieve a minimum 596 participants who contribute primary outcome data. Randomization will be stratified by study site and sex: 332 women and 332 men. Participants will be randomized 1:1 to a 3-day regimen of doxycycline or a 7-day regimen of doxycycline. The study blind will be maintained by providing 7 days of identical pre-filled blister packs, one with 3 days of active treatment and 4 days of placebo, and the other with 7 days of active treatment. Participants will be asked to return 28 days after randomization (at day 29), at which time they will be re-tested for chlamydia (CT) using a laboratory-based chlamydia (CT) nucleic acid amplification test (NAAT).
Interventions
- OTHER Placebo
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2026-02-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05840159
The ClinicalTrials.gov registry entry for NCT05840159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 526 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05840159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05840159 about?
NCT05840159 is a clinical study titled "A Study of Doxycycline to Treat Chlamydial Infection". This is a Phase 4 blinded, randomized, active-controlled, non-inferiority trial. Final evaluable population will include a minimum 596 individuals: 298 women with confirmed urogenital chlamydia (CT) and 298 men with confirmed rectal chlamydia (CT). Approximately 664 participants will be enrolled to ...
What is the current status of trial NCT05840159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 526 participants. The study started on 2024-01-19. Estimated completion is 2026-02-12.
What interventions are being tested in trial NCT05840159?
The interventions under investigation include: Placebo (OTHER), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT05840159?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.